medigraphic.com
Asociación Mexicana de Gastroenterología

2005, Number 1

Next >>

Rev Gastroenterol Mex 2005; 70 (1)

Prevalence of different groups that comprise endoscopy-negative reflux disease

Carmona-Sánchez R, Solana-Sentíes S, Esmer-Sánchez D, Alvarez TFJF

Language: Spanish
References: 24
Page: 6-12
PDF size: 79.05 Kb.


ABSTRACT

Background data: Endoscopic-negative reflux disease (ENRD) is a heterogeneous population. There are few data regarding the prevalenece of each group and subgroups that constitutes ENRD population. Objective: To describe the prevalence of the differents groups and subgroups in ENRD. Patients and methods: We studied consecutive patients with frequent heartburn and acid regurgitation with endoscopically normal esophageal mucosa in whom ambulatory 24-h esophageal pH monitoring was performed. According with the pH-testing data and the correlation between symptoms and the acid reflux events, the subjects were classified in two groups: non-erosive gastroesophageal reflux disease (NERD) and functional heartburn. The functional heart-burn group was splited in 3 subgroups: asymptomatics during pH-monitoring, hipersensitive esophagus and those with physiologic reflux with negative association between symptoms and acid reflux events. These last subgroup was classified in: minute changes of intra-esophegeal pH (upper than 4, n = 19) and non-acid related stimuli. Results: One hundred and eleven patients with ENRD were classified in NERD (28%, n = 31) and functional heartburn (72%, n = 80). Patients with functional heartburn were classified in asymptomatics during pH-monitoring (11%, n = 12), hipersensitive esophagus (9%, n=10) and those with physiologic reflux with negative association between symptoms and acid reflux events (52%, n = 58). In these last subgroup 19 (17%) patients were classified as minute changes of intra-esophegeal pH (upper than 4) and 39 (35%) as non-acid related stimuli. Conclusions: Even most of the patients with ENRD have normal ambulatory pH-test, their symptoms are related with drops of esophageal pH in 26% of the cases. Eleven percent do not have symptoms during ambulatory pH-monitoring.


REFERENCES

  1. Dent J, Brun F, Fendrick AM, Fennnerty MB, Janssens J, Kahrilas PJ y cols. An evidence-based appraisal of reflux disease management-the Genval Workshop Report. Gut 1999; 44(Suppl 2): S1-S16.

  2. Quigley EMM. New developments in the patophysiology of gastroesofageal reflux disease (GERD): implications for patient management. Aliment Pharmacol Ther 2003; 17(Suppl. 2): 43-51.

  3. Achem SR. Endoscopy negative gastroesophageal reflux disease: the hypersensitive esophagus. Gastroenterol Clin North Am 1999, 28: 893-904.

  4. Fass R. Epidemiology and pathophysiology of symptomatic gastroesphageal reflux disease. Am J Gastroenterol 2003; 98(Suppl. 3): S2-S7.

  5. Fass R. Pirosis funcional: el estímulo, el dolor y el cerebro. En: Valdovinos MA, Milke P, Uscanga L. Gastroenterología, hepatología y nutrición basadas en evidencia. 1ra. Edición. México: Masson; 2002, p. 47-60.

  6. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 10 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastroesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965-73.

  7. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: An internation study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998: 10: 119-24.

  8. Martínez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD) – acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 537-45.

  9. Frazzoni M, de Micheli E, Savarino V. Different patterns of esophageal acid exposure distinguish complicated reflux disease from either erosive reflux esophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 2003; 18: 1091-8.

  10. Remes-Troche JM, Gómez-Escudero O, Ruíz JC, Schmulson MJ, Valdovinos MA. Percepción de síntomas de descensos mínimos en el pH esofágico en pacientes con enfermedad por reflujo erosiva y no erosiva. Rev Gastroenterol Méx 2003; 68(Suppl. 3): 83.

  11. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002; 51: 885-92.

  12. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease –current concepts and dilemmas. Am J Gastroenterol 2001; 96: 303-14.

  13. Carmona-Sánchez R, Valerio-Ureña J, Valdovinos-Díaz MA. Utilidad de la lidocaína en gel en la manometría esofágica. Rev Gastroenterol Méx 2001; 66: 137-40.

  14. Dekel R, Pearson T, Wendel C, De Garmo P, Fennerty MB, Fass R. Assessment of esophageal motor function in patients with dysphagia or chest pain – the clinical outcomes research initiative experience. Aliment Pharmacol Ther 2003; 18: 1083-9.

  15. Richter JE, Bradley LA, DeMeester TR. Normal 24-hour ambulatory esophageal pH values: influence of study center, pH electrode, age and gender. Dig Dis Sci 1992; 37: 849-56.

  16. Singh S, Richter JE, Bradley LA. The symptom index: differential usefulness in suspected acid-related complaints of heartburn and chest pain. Dig Dis Sci 1993; 38: 1402-8.

  17. Tack J, Fass R. Review article: approaches to endoscopic negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther 2004; 19(Suppl. 1): 28-34.

  18. Vargas-Vorácková F. Epidemiología clínica para el internista. En: Uribe M. Tratado de Medicina Interna. 1ra edición. México: Méndez-Oteo; 1988, p. 2765-88.

  19. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 953-6.

  20. Pace F, Santalucia F, Bianci Porro C. Natural history of gastro-oesophageal reflux disease without esophagitis. Gut 1991; 32: 845-8.

  21. Fass R, Ofman JJ. Gastroesophageal reflux disease -should we adopt a new conceptual framework. Am J Gastroenterol 2002; 97: 1901-9.

  22. Valdovinos MA, Soto JC, Schmulson MJ, Icaza ME, Vargas F. Frequency of different subgroups of patients with non erosive gastroesphageal reflux disease (NERD) according to esophegeal acid exposure and symptom index. Gastroenterology 2003; 124(Suppl. 1): A538.

  23. Soto-Pérez JC, Icaza ME, Vargas F, Valdovinos-Díaz MA. Enfermedad por reflujo gastroesofágico no erosiva. Frecuencia de sus variedades clínicas, características de la exposición esofágica al ácido y correlación sintomática. Rev Gastroenterol Méx 2003; 68: 113-19.

  24. Ward EM, DeVault KR, Bouras EP, et al. Successful oesophageal pH monitoring with a catheter-free system. Aliment Pharmacol Ther 2004; 19: 449-54.




2020     |     www.medigraphic.com